Aesthetic technologies are expanding ophthalmic practice into a broader sphere of patient care. AAO 2025 emphasized that ...
Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving ...
Optogenetics offers mutation-independent vision restoration for IRDs, with promising early-phase results in retinitis ...
Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving ...
AAO 2025 revealed that true-color widefield imaging, AI-powered home OCT, and refined FAERS analyses are collectively transforming retinal diagnostics into a more precise, continuous, and safety-aware ...
Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific ...
Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...
Foundation Fighting Blindness has granted public access to de-identified 4-year data from individuals participating in RUSH2A ...
Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO
The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...
Precise Bio has successfully treated a patient with PB-001, the company’s 3D-bio-printed corneal implant, at Rambam Medical ...
The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...
Coave Therapeutics has announced its lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback